Novel safe GR-targeted therapy for hematological malignancies

Glucocorticoids (Gcs) have been widely and successfully used to treat a broad spectrum of hematological malignancies, and the glucocorticoid receptor (GR) is a well-known anti-cancer target. Unfortunately, most patients chronically treated with Gcs develop numerous deleterious metabolic and atrophic side effects that strongly affect the quality of their life. Thus, there is a great need for the development of safer GR-targeted therapies.